Updated:
Neovision Capital
Neovision Capital is a Shanghai-based venture firm targeting seed through late-stage investments in mainland China.
Neovision Capital
Neovision Capital, a Shanghai-based private equity manager, focuses on venture and growth-stage investments in China. The firm's stated strategy covers the full spectrum from seed and start-up phases through expansion and late-stage venture, though limited public disclosure obscures specific sector concentrations or deal history. The firm's website lists early-stage and venture generalist mandates, suggesting a model that can participate in both initial rounds and follow-on growth financing — a common structure among Chinese venture shops that aim to hold positions from inception to pre-IPO. Without accessible portfolio-level data, the geographic footprint appears confined to mainland China, consistent with domestic-focused vehicles of this vintage. Scale, team composition, and fundraising track record remain opaque. The Shanghai headquarters place Neovision Capital in a competitive ecosystem alongside hundreds of similarly structured venture firms, but no adjacent vehicles, philanthropic arms, or co-investment clubs are evident from the firm's own communications. As of the most recent update in May 2026, Altss research notes no recent operational announcements or confirmed deployment milestones. Neovision Capital's structural posture is challenging to differentiate given the data gap. The architecture — a generalist venture mandate operating from a single office in Shanghai — is typical of the asset class, and no unique succession, regulatory, or sourcing model is discernible from available public record.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Frequently asked questions
What investment stages does Neovision Capital cover?
The firm's stated mandate spans the full venture lifecycle, from seed and start-up rounds through expansion and late-stage growth. This positions Neovision Capital to enter at formation and follow on through later fundraises, though specific check-size ranges or stage concentrations have not been publicly disclosed.
How does the firm source deal flow in China's venture market?
Sourcing mechanics are not documented in the firm's public materials. Given the Shanghai base and generalist venture strategy, typical channels would include domestic incubators, university spin-out networks, and local government-guided funds — but no primary evidence confirms Neovision Capital's specific origination approach.
Is Neovision Capital open to co-investments alongside external GPs?
The firm has not published co-investment policies or preferences. While many Chinese venture managers syndicate rounds, Neovision Capital's public record provides no guidance on whether it leads rounds, follows, or shares allocations with domestic or international co-investors.
What sectors does Neovision Capital target?
No sector-specific focus areas are declared on the firm's website. The venture-generalist label suggests broad exposure across technology, consumer, and potentially healthcare verticals common among China-domiciled funds, but any such attribution remains unverified.
Who leads investment decisions at the firm?
Neovision Capital has not disclosed its GP bench or investment committee structure. No named principals are available through regulatory filings, press coverage, or the firm's own digital presence, leaving the leadership team entirely opaque to outside allocators.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: